BIAF 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-07

• We develop noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of AI. Our commercial test, CyPath® Lung, is a noninvasive diagnostic that analyzes sputum using flow cytometry and au…

• ● The Company raised approximately $3.2 million in gross proceeds from an equity transaction in the second quarter to fund operating activities.

• ●In July 2026, the Company surpassed the total number of tests completed in all of 2025, delivering more than 1,200 CyPath® Lung test reports to physicians.

• ●The number of physician offices and clinics ordering CyPath® Lung for their patients increased 122% during the second quarter of 2026 compared to the same period in 2025.

• ●In July 2026, the Company received notice from Nasdaq noting the Company’s bid price for its Common Stock closed at less than $1 per share over the previous 30 consecutive business days as of July 29, 2026, and has not regained compliance according to Listing Rule 5550(a)(2). As of August 6, 2026 t…

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• We develop noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of AI. One of our diagnostic tests analyzes cell populations, including cancer and cancer-related cells, that are indi…

• ● Consolidated revenue decreased approximately 36% to $1.4 million for the three months ended March 31, 2026 as compared to $1.9 million for the three months ended March 31, 2025.

• ● In April 2026, CyPath® Lung test was featured at the invitation-only “Advances in Early Lung Cancer Detection” symposium at the Cleveland Clinic in Cleveland, Ohio.

• ● In March 2026, we enrolled our first patient in our clinical trial entitled “Detection of Early-Stage Lung Cancer in Sputum using Flow Cytometry and an Automated Analysis Pipeline” (NCT07168993). The John P. Murtha Cancer Center Research Program (MCCRP), a research program within the Department of…

• ● In March 2026, we announced an additional patient case studies where a CyPath® Lung result of “Unlikely Malignancy” relieved patient anxiety and supported the physician’s decision to continue repeat imaging rather than subjecting patients to invasive, risky and costly biopsies. The case study adds…

相对上期新增的文字 · 来源:10-Q · 2026-08-07

• During the fiscal quarter ended June 30, 2026, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any…

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• During the three months ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.